Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the limitations of biomarkers in melanoma.
Video Reports
Dr. Chandra on the Incidence of Targetable Mutations in Melanoma
Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the incidence of targetable mutations in melanoma.
Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, discusses measuring tumor mutational burden (TMB) in patients with non–small cell lung cancer (NSCLC) who received prior immunotherapy.
Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma
Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses unanswered questions regarding the utility of targeted therapy in melanoma.